Brainstorm cell therapeutics presents nurown® phase 2 progressive ms biomarker data at the 38th ectrims congress

Biomarker analyses show robust increases in cerebrospinal fluid neuroprotective biomarkers following nurown treatment new york , oct. 20, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced that a scientific abstract titled 'nurown (msc-ntf) phase 2 clinical trial in progressive ms: effects on csf neuroprotective biomarkers' will be presented at the 38th congress of the european committee for treatment and research in multiple sclerosis (ectrims), being held from october 26-28 th in amsterdam, nl.     cerebrospinal fluid (csf) biomarker analyses from the phase 2 progressive ms clinical trial demonstrate that intrathecal nurown treatment resulted in robust increases in csf neuroprotective biomarkers, consistent with the proposed mechanism of action, and provide important biological context for the observed clinical trial outcomes.
BCLI Ratings Summary
BCLI Quant Ranking